Current opinion on optimal systemic treatment for metastatic colorectal cancer: Outcome of the ACTG/AGITG expert meeting ECCO 2013

Expert Review of Anticancer Therapy

Volumn 14, Issue 12, 2014, Pages 1477-1493

  Price, Timothy J ^a   Segelov, Eva ^b   Burge, Matthew ^c   Haller, Daniel G ^d   Tebbutt, Niall C ^e   Karapetis, Christos S ^f   Punt, Cornelis J A ^g   Pavlakis, Nick ^h   Arnold, Dirk ⁱ   Gibbs, Peter ^j   Shapiro, Jeremy D ^k  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e AUSTIN HEALTH   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ TUMOR BIOLOGY CENTER   (Germany)

^j Royal Melbourne and Monash Hospitals   (Australia)

^k MONASH UNIVERSITY   (Australia)

more..

Author keywords

biological; chemotherapy; colorectal cancer; consensus; RAS; VEGF

Indexed keywords

AFLIBERCEPT; B RAF KINASE; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; DABRAFENIB; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; NERATINIB; OXALIPLATIN; PANITUMUMAB; PLACEBO; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TAS 102; UNCLASSIFIED DRUG; VATALANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; COMORBIDITY; CONTINUOUS INFUSION; DELAYED DIAGNOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FERTILITY PRESERVATION; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GERIATRIC PATIENT; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; LIVER METASTASIS; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; NEUROTOXICITY; NEUTROPENIA; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PEROPERATIVE COMPLICATION; PROGRESSION FREE SURVIVAL; PROTEINURIA; PSYCHOSOCIAL CARE; RASH; REVIEW; SENSORY NEUROPATHY; SKIN TOXICITY; SURVIVAL RATE; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT; COLORECTAL NEOPLASMS; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 84911894801     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.949678     Document Type: Review

References (97)

1. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23(36): 9441-2
2. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363(8):733-42
3. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240(4):644-57.discussion 657-648
4. Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007;12(1):38-50
5. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37
6. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370(9582):143-52
7. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23(22): 4866-75
8. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25(30): 4779-86
9. Punt CJ, Koopman M. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol 2008; 26(11):1907-8.author reply 1908-1909
10. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum - Applying current evidence to clinical practice. Cancer Treat Rev 2012; 38(5):397-406
11. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25(13):1670-6
12. Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94(6): 798-805
13. Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014;50(1): 57-63
14. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23):2335-42
16. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-44
17. Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012;30(36):4566-72
18. Miriam Koopman LS, May AM, Mol L, et al. Final results and subgroup analyses of the phase 3 CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). In: J Clin Oncol 2014. 32:(Suppl 5). ASCO, Chicago
19. Puthillath A, Patel A, Fakih MG. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. OncoTargets Ther 2009;2:1-15
20. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37
21. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506
22. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863): 303-12
23. Tabernero J, Van Cutsem E, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50(2):320-31
24. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
25. Clarke SJ, Karapetis CS, Gibbs P, et al. Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hematol 2012
26. Price TJ, Bruhn B, Lee C, et al. Correlation of PI3KCA and extended RAS gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC). In: J Clin Oncol 2014. 32:(Suppl 5):abstract 3539 ASCO Chicago
27. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations n colorectal cancer. N Engl J Med 2013;369(11):1023-34
28. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer. J Clin Oncol 2014
29. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753-62
30. Loupakis F, Ruzzo A, Cremolini C, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009;101(4):715-21
31. Stintzing AJ, Rossius L, Modest DP, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. In: ECCO. EJC, Amsterdam, 2013
32. Peeters M, Oliner KS, Price TJ, et al. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). In: J Clin Oncol 2014. 32:(Suppl 5):abstr 3568 Chicago
33. Seymour MT, Richman S, Middleton GW, et al. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). In: J Clin Oncol 2011. abstr 3523
34. Peeters M, Oliner KS, Parker A, et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 2013;19(7):1902-12
35. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011;377(9783): 2103-14
36. Alan P, Venook DN, Lenz H-J, et al. Bertagnolli, Charles David Blanke, Cancer and Leukemia Group B (Alliance), SWOG, and ECOG. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). In: J Clin Oncol. Chicago, 2014
37. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
38. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27(5): 672-80
39. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nature reviews. Clin Oncol 2009; 6(8):465-77
40. McCahill LE, Yothers G, Sharif S, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol 2012;30(26):3223-8
41. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol 2011;18(12): 3252-60
42. Lise M, Da Pian PP, Nitti D, Pilati PL. Colorectal metastases to the liver: present results and future strategies. J Surg Oncol. (Suppl) 1991;2:69-73
43. Bismuth H, Adam R, Navarro F, et al. Re-resection for colorectal liver metastasis. Surg Oncol Clin N Am 1996;5(2):353-64
44. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8(4): 347-53
45. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16(8):1311-19
46. Leichman L. The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer. Surg Oncol Clin N Am 2007;16(3):537-56.viii-ix
47. Zdenkowski N, Chen S, van der Westhuizen A, Ackland S. Curative strategies for liver metastases from colorectal cancer: a review. Oncologist 2012;17(2): 201-11
48. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34
49. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J 2010;16(2):125-31
50. Bokemeyer C, Cutsem EV, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012;48(10): 1466-75
51. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(31):4706-13
52. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
53. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11(1): 38-47
54. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 2014;15(6):601-11
55. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370(9582):135-42
56. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol 2011;12(11):1032-44
57. Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28(19):3191-8
58. Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 2011
59. Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013;14(11): 1077-85
60. Price TJ, Townsend AR, Beeke C, et al. "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again? Asia Pac J Clin Oncol 2012;8(1):10-13
61. Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003;30(4 Suppl 15): 14-19
62. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005;19(8):1057-63.discussion 1063-1054, 1069
63. Ong SY, Clarke SJ, Bishop J, et al. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti Cancer Drugs 2001;12(7): 619-25
64. van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics 2013;14(7): 799-811
65. Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol 2012
66. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27(19):3109-16
67. Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011;117(16):3630-40
68. Sundermeyer ML, Meropol NJ, Rogatko A, et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5(2):108-13
69. Saridaki Z, Papadatos-Pastos D, Tzardi M, et al. BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 2010;102(12):1762-8
70. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65(14): 6063-9
71. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
72. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22(7): 1535-46
73. Seymour MT, Brown SR, Richman S, et al. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol 2011; 29:Suppl; abstract 3523
74. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361(1):98-9
75. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
76. Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers. Expert Rev Mol Med 2012;14:e17
77. Vemurafenib, cetuximab, and irinotecan in advanced solid cancers. Available from: http://clinicaltrials.gov/show/NCT01787500
78. Lieu LR, De Gramont A, Maughan TS, et al. The impact of young age on survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. In: EJC. Amsterdam, 2013
79. Vatandoust S, Padbury R, Roder D, et al. Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry. In: J Clin Oncol 2014. 32(Suppl; abstr e17584) Chicago
80. Salem M, Stanski N, Dyson G, et al. Clinico-pathological characteristics of younger, middle aged, and older patients with colon cancer. In: EJC. Amsterdam, 2013
81. Seymour MT, Punt CJ. CAIRO and FOCUS. Lancet 2007;370(9603):1904-5; author reply 1905
82. Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012;13(10):e437-44
83. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 2006;24(3):394-400
84. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27(34):5727-33
85. Labianca R, Sobrero A, Isa L, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol 2011;22(5):1236-42
86. Neo EL, Beeke C, Price T, et al. South Australian clinical registry for metastatic colorectal cancer. ANZ J Surg 2011;81(5): 352-7
87. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2012
88. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(14):2311-19
89. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757-65
90. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15(6):569-79
91. Grothey A, Siena S, Falcone A, et al. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol 2012. LBA385
92. Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012;13(10): 993-1001
93. Yoshino T, Falcone A, Ohtsu A, et al. Results of a multicenter, randomized, double-blind, Phase III study of TAS-102 VS. placebo, with best supportive care (BSC), in patients (PTS) with metastatic colorectal cancer (MCRC) refractory to standard therapies (RECOURSE). In: Ann Oncol 2014. 25(Suppl 2): ii114-Barcelona
94. Lillian L, Siu JD, Derek J, et al. Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. In: J Clin Oncol 2012. 386
95. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9
96. Garcia-Carbonero R, Rivera F, Maurel J, et al. An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist 2014;19(4):350-1
97. A study in second line metastatic colorectal cancer. Available from: http://clinicaltrials. gov/show/NCT01183780